Litcius/Paper detail

Photoactivatable Immunostimulatory Nanomedicine for Immunometabolic Cancer Therapy

Wencheng Wu, Yinying Pu, Bangguo Zhou, Yucui Shen, Shuang Gao, Min Zhou, Jianlin Shi

2022Journal of the American Chemical Society77 citationsDOI

Abstract

A rationally designed immunostimulant (CC@SiO2-PLG) with a photoactivatable immunotherapeutic function for synergetic tumor therapy is reported. This CC@SiO2-PLG nanoplatform comprises catalase and a photosensitizer (Ce6) co-encapsulated in a silica capsule, to which an immunostimulant is conjugated through a reactive oxygen species-cleavable linker. After accumulating in tumor tissue, CC@SiO2-PLG generates O2 to relieve tumor hypoxia and promotes the production of singlet oxygen (1O2) upon laser irradiation, resulting in not only tumor destruction but also the release of tumor-associated antigens (TAAs). Simultaneously, the linker breakage by the photoproduced 1O2 leads to the remote-controlled release of conjugated indoleamine 2,3-dioxygenase (IDO) inhibitor from CC@SiO2-PLG and consequent immunosuppressive tumor microenvironment reversion. The released TAAs in conjunction with the inhibition of the IDO-mediated tryptophan/kynurenine metabolic pathway induced a boosted antitumor immune response to the CC@SiO2-PLG-mediated phototherapy. Therefore, the growth of primary/distant tumors and lung metastases in a mouse xenograft model was greatly inhibited, which was not achievable by phototherapy alone.

Topics & Concepts

ChemistryPhotosensitizerIndoleamine 2,3-dioxygenaseCancer researchTumor microenvironmentImmunostimulantImmune systemTumor hypoxiaPhotodynamic therapyBiochemistryImmunologyTryptophanTumor cellsRadiation therapyAmino acidMedicineInternal medicineBiologyOrganic chemistryNanoplatforms for cancer theranosticsCancer, Stress, Anesthesia, and Immune ResponseCancer Immunotherapy and Biomarkers
Photoactivatable Immunostimulatory Nanomedicine for Immunometabolic Cancer Therapy | Litcius